Skip to main content

Table 1 Characteristics of the included prospective cohort studies

From: Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies

Study

Region

N

Age

Male/female

Schedule

Child-Pugh

CLIP (0/1/2/3/4)

Prior therapy

ECOG (0/1/2)

BCLC (A/B/C)

Liver disease

Line of therapy

Melanie 2018 [28]

USA

90

61

NA

Arm1: S(400 mg, Q2D, oral)

Arm2: B (10 mg/kg, Q2w) + E (150 mg/d, oral)

S:A88%;B12%

B + E:A83%;B17%

S:4/10/17/9/3

B + E:7/10/16/8/6

NA

S:17/25/1

B + E: 15/32/0

S: A9%B26%C65%

B + E: A2%B30%C68%

NA

First

Kaseb 2016 [24]

Egypt

44

63

33/11

B(10 mg/kg, Q2w) + E(150 mg/d, oral)

A98%, B2%

5/17/12/7/0

Sorafenib

15/29/0

A5%B2%C93%

HBV8; HCV13

Alcoholism10 Cirrhosis19

Second

Govindarajan 2013 [21]

USA

21

60

13/8

B(15 mg/kg, Q3w) + E(150 mg/d, oral)

A85.7%, B14.3%

NA

NA

NA

A0%B23.8% C76.2%

HBV1; HCV6

HCV + HBV2

First

Hsu 2013 [22]

Taiwan

51

58

44/7

B(5 mg/kg, Q2w) + E (150 mg/d, oral)

A98%, B2%

15/8/11/12/5

NA

30/20/1

A0% B11.7%

C88.3%

HBV42;HCV4 HBV + HCV3

First

Philip 2012 [25]

USA

27

60

20/7

B(10 mg/kg, Q2w) + E(150 mg/d, oral)

A74%, B26%

NA

Sorafenib

16/11/0

NA

HBV1; HCV8

Alcoholism2; Cirrhosis6

Second

Yau 2012 [27]

China

10

47

7/3

B(10 mg/kg, Q2w) + E(150 mg/d, oral)

A100%

NA

Sorafenib

0/10/0

A0% B10%,

C90%

HBV10

Cirrhosis10

Second

Kaseb 2012 [23]

USA

59

64

13/46

B(10 mg/kg, Q2w) + E(150 mg/d, oral)

A86%

B14%

3/14/13/22/7

Sorafenib(7/59)

NA

A3.4%B20.3% C76.3%

HBV10; HCV17

Alcoholism 27

NA

Melanie 2009 [26]

USA

40

64

31/9

B(10 mg/kg, Q2w) + E(150 mg/d, oral)

A87.5%,

B12.5%

2/11/6/16/5

Sorafenib(8/40)

19/20/1

A5%B30% C65%

HBV6; HCV10

Alcoholism17 Cirrhosis27

NA

  1. Note: B bevacizumab, E erlotinib, S sorafenib, NA not available